Get the latest news, insights, and market updates on DAWN (Day One Biopharmaceuticals, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:00 p.m. EST. A live webcast of the discussion will be available by Nov 18, 2025 - $DAWN
How the Acquisition Is Reshaping Mersana Therapeutics’ Story and Analyst Outlook
Shares of Mersana Therapeutics have seen their consensus analyst price target increase from $28.29 to $33.20 per share. This reflects a significant boost in confidence following a major acquisition announcement. The upward revision is supported by a modest decrease in the discount rate, which signals lower perceived risk and greater optimism around the company’s long-term prospects. Stay tuned as we explore how investors can track ongoing shifts in sentiment and updates to the company’s... Nov 15, 2025 - $DAWN
Day One Biopharmaceuticals (DAWN): Examining Valuation Following Recent Share Price Rebound
Day One Biopharmaceuticals (DAWN) shares have been on the move recently, catching the attention of investors looking for value in the biotech space. The company has posted significant swings over the past month, drawing questions about what might be driving sentiment. See our latest analysis for Day One Biopharmaceuticals. While Day One Biopharmaceuticals’ share price has rebounded sharply, posting a 25.5% gain over the past month and up more than 31% in the last 90 days, its one-year total... Nov 14, 2025 - $DAWN
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc.Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 millionClosing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focuse Nov 14, 2025 - $DAWN
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
Acquisition expands Day One’s portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 (ACC-1), a cancer with high unmet need and a lack of therapeutic options Day One will apply existing scientific and commercial capabilities to this investigational innovative therapeutic with a clear potential registration path Company to host conference call and webcast toda Nov 13, 2025 - $DAWN
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million Closing is expected to occur by the end of January 2026 CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug Nov 13, 2025 - $DAWN
Day One snaps up ADC maker Mersana in backloaded buyout deal
After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only materialize if its main cancer drug hits a variety of milestones. Nov 13, 2025 - $DAWN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple